TY - JOUR
T1 - Dosage changes of a segment at 17p13.1 lead to intellectual disability and microcephaly as a result of complex genetic interaction of multiple genes
AU - Carvalho, Claudia M.B.
AU - Vasanth, Shivakumar
AU - Shinawi, Marwan
AU - Russell, Chad
AU - Ramocki, Melissa B.
AU - Brown, Chester W.
AU - Graakjaer, Jesper
AU - Skytte, Anne Bine
AU - Vianna-Morgante, Angela M.
AU - Krepischi, Ana C.V.
AU - Patel, Gayle S.
AU - Immken, La Donna
AU - Aleck, Kyrieckos
AU - Lim, Cynthia
AU - Cheung, Sau Wai
AU - Rosenberg, Carla
AU - Katsanis, Nicholas
AU - Lupski, James R.
N1 - Publisher Copyright:
© 2014 by The American Society of Human Genetics. All rights reserved.
PY - 2014
Y1 - 2014
N2 - The 17p13.1 microdeletion syndrome is a recently described genomic disorder with a core clinical phenotype of intellectual disability, poor to absent speech, dysmorphic features, and a constellation of more variable clinical features, most prominently microcephaly.We identified five subjects with copy-number variants (CNVs) on 17p13.1 for whom we performed detailed clinical and molecular studies. Breakpoint mapping and retrospective analysis of published cases refined the smallest region of overlap (SRO) for microcephaly to a genomic interval containing nine genes. Dissection of this phenotype in zebrafish embryos revealed a complex genetic architecture: dosage perturbation of four genes (ASGR1, ACADVL, DVL2, and GABARAP) impeded neurodevelopment and decreased dosage of the same loci caused a reduced mitotic index in vitro. Moreover, epistatic analyses in vivo showed that dosage perturbations of discrete gene pairings induce microcephaly. Taken together, these studies support a model in which concomitant dosage perturbation of multiple genes within the CNV drive the microcephaly and possibly other neurodevelopmental phenotypes associated with rearrangements in the 17p13.1 SRO.
AB - The 17p13.1 microdeletion syndrome is a recently described genomic disorder with a core clinical phenotype of intellectual disability, poor to absent speech, dysmorphic features, and a constellation of more variable clinical features, most prominently microcephaly.We identified five subjects with copy-number variants (CNVs) on 17p13.1 for whom we performed detailed clinical and molecular studies. Breakpoint mapping and retrospective analysis of published cases refined the smallest region of overlap (SRO) for microcephaly to a genomic interval containing nine genes. Dissection of this phenotype in zebrafish embryos revealed a complex genetic architecture: dosage perturbation of four genes (ASGR1, ACADVL, DVL2, and GABARAP) impeded neurodevelopment and decreased dosage of the same loci caused a reduced mitotic index in vitro. Moreover, epistatic analyses in vivo showed that dosage perturbations of discrete gene pairings induce microcephaly. Taken together, these studies support a model in which concomitant dosage perturbation of multiple genes within the CNV drive the microcephaly and possibly other neurodevelopmental phenotypes associated with rearrangements in the 17p13.1 SRO.
UR - http://www.scopus.com/inward/record.url?scp=84922325674&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2014.10.006
DO - 10.1016/j.ajhg.2014.10.006
M3 - Article
C2 - 25439725
AN - SCOPUS:84922325674
SN - 0002-9297
VL - 95
SP - 565
EP - 578
JO - American journal of human genetics
JF - American journal of human genetics
IS - 5
ER -